Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts START San Antonio, San Antonio, Texas NEXT Virginia, Fairfax, Virginia South Korea
Asan Medical Center, Seoul Samsung Medical Center, Seoul